Harnesses the power of T-cell therapy to treat cancer, focusing on engineered TCRs to target and destroy cancer cells.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company specializing in innovative cell therapies for solid tumors, operating primarily in the United States and the United Kingdom. Leveraging its specific peptide enhanced affinity receptor (SPEAR) T-cell platform, the company identifies cancer targets with precision. Currently, Adaptimmune is advancing ADP-A2M4 through phase II clinical trials, including SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma (MRCLS), and SPEARHEAD-2 for head and neck cancer. Additionally, it is conducting phase I trials for multiple cancers such as urothelial, melanoma, and non-small cell lung cancers.
In its commitment to advancing treatment options, Adaptimmune is also developing ADP-A2AFP for hepatocellular carcinoma and ADP-A2M4CD8 for various cancers, including lung and ovarian cancers, through ongoing phase I clinical trials. The company has established significant collaborations and partnerships to enhance its research and development efforts. These include agreements with GSK, Noile-Immune Biotech Inc., Alpine Immune Sciences, and the National Center for Cancer Immune Therapy in Denmark. Furthermore, strategic alliances with the MD Anderson Cancer Center and Universal Cells, Inc. underscore Adaptimmune's dedication to pioneering therapies that harness the immune system to combat cancer.
Founded in 2008 and headquartered in Abingdon, UK, Adaptimmune Therapeutics plc continues to push the boundaries of immunotherapy. Its strategic collaboration and license agreements with Genentech, Inc. and F. Hoffman-La Roche Ltd further highlight its commitment to developing personalized alllogeneic T-cell therapies utilizing aß T-cell receptors. With a robust pipeline and a global network of collaborators, Adaptimmune remains at the forefront of advancing novel treatments for patients in need.